trending Market Intelligence /marketintelligence/en/news-insights/trending/lTGPwaPGa8kmnAqRXL2XUw2 content esgSubNav
In This List

Sanofi sues Merck & Co. unit over patents for insulin drug

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Sanofi sues Merck & Co. unit over patents for insulin drug

Sanofi sued Merck Sharp & Dohme Corp. alleging that the Merck & Co. Inc. unit infringed on two patents for its insulin product Lantus.

The suit, filed in the U.S. District Court for the District of New Jersey, was triggered by notification from Merck in June that it had filed a new drug application with the U.S. Food and Drug Administration for an insulin glargine vial drug product.

Merck's application included a certification challenging all Sanofi patents listed in the FDA orange book for Lantus and Lantus SoloStar products.